GSK receives FDA approval for lung cancer drug Jideytro
GlaxoSmithKline (GSK) received FDA approval for its new lung cancer therapy, Jideytro. The once-daily tablet is a kinase inhibitor developed through GSK's $10.6 billion acquisition of Nuvalent.
Tickers: $GSK